Dr Lal Pathlabs Share Price Target 2025, 2026, 2030, 2040, 2050

Dr Lal PathLabs is a well-known Indian company that provides many kinds of medical tests and health services. It offers simple and advanced tests in areas like pathology, radiology, genetics, and microbiology, including tests for dengue, diabetes, infections, and autoimmune diseases. The company has a big network of labs, patient service centres, and it serves people, hospitals, doctors, and companies. It also works in other countries like Nepal, Saudi Arabia, Nigeria, Bangladesh, and Sri Lanka.

What is Dr Lal Pathlabs Ltd NSE: LALPATHLAB?

Dr Lal PathLabs, established in 1949 in Delhi by Dr S. K. Lal. It is one of India’s biggest and most trusted medical testing companies. It began as a small lab and has now grown into a large network with many labs and thousands of testing centres all over India. The company does simple and advanced health tests, like blood tests, urine tests, thyroid tests, diabetes tests, infection tests, and full-body checkups. It also offers special tests for the heart and other organs. Because it has centres in many cities and towns, people can easily get tested, and its good quality makes doctors, hospitals, and patients trust its reports.

Dr Lal Pathlabs Share Price Target

Dr Lal Pathlabs Share Price Target 2025

It is one of India’s most trusted medical testing companies. It helps people understand their health by doing many types of tests. The company has been helping patients for many years and is known for giving correct and dependable reports. It offers simple tests like blood checks as well as advanced health tests. Because it has many centres across India, people can easily find a nearby place to get tested without travelling far. In 2025, its share price target would be ₹3674, as per stock market analysts.

Its share price would be between ₹2293 to ₹3674 in 2025, as per stock market analysts.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2025	2293	3674

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	2666	3143
February	2300	2893
March	2293	2628
April	2351	2979
May	2708	2906
June	2730	3029
July	2742	3175
August	3085	3506
September	3102	3540
October	3002	3235
November	2891	3500
December	2779	3674

Dr Lal Pathlabs Share Price Target 2026

It started as a small lab in Delhi many years ago. Over time, it grew into one of the biggest testing networks in India. Today, it has many labs and thousands of centres where people can give their samples. This large network helps people in villages, towns, and cities get important health tests easily. The company keeps growing by adding new machines, hiring trained staff, and opening new centres in places where testing is needed. In 2026, its share price target would be ₹4979, as per stock market analysts.

Its share price would be between ₹3484 to ₹4979 in 2026, as per stock market analysts.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2026	3484	4979

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	3484	3747
February	3500	3884
March	3579	4000
April	3612	4074
May	3689	4120
June	3712	4187
July	3758	4235
August	3858	4284
September	3971	4390
October	4058	4558
November	4325	4785
December	4557	4979

Share Price Target 2027

It offers a very long list of tests for different health needs. These include basic tests like blood sugar, thyroid, kidney, liver, cholesterol, urine tests, and tests for infections. It also offers special tests like genetic tests, allergy tests, hormone tests, cancer-related tests, vitamin tests, and tests for autoimmune diseases. This helps doctors quickly find health problems and give the right treatment. The company keeps adding new tests as medical needs change. In 2027, its share price target would be ₹6308, as per stock market analysts.

Its share price would be between ₹4725 to ₹6308 in 2027, as per stock market analysts.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2027	4725	6308

Share Price Target 2028

It also provides services like X-rays, ultrasounds, CT scans, and other scans. These tests help doctors see inside the body and find problems that blood tests cannot show. Imaging is very important for spotting bone fractures, organ issues, infections, tumours, and other health problems. The company uses modern machines and trained radiologists to make sure the images are clear and the reports are correct. In 2028, its share price target would be ₹7572, as per stock market analysts.

Its share price would be between ₹6180 to ₹7572 in 2028, as per stock market analysts.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2028	6180	7572

Share Price Target 2029

It has many health checkup packages for different people. These include full-body checkups, heart checkups, diabetes checkups, pregnancy packages, and checkups for older people. Each package includes important tests that help people know their overall health and find any early problems. These packages cost less than doing all tests separately, so they are more affordable. Many people choose them for regular health checkups because early testing helps avoid serious health issues and keeps them healthy for a long time. In 2029, its share price target would be ₹8728, as per stock market analysts.

Its share price would be between ₹7378 to ₹8728 in 2029, as per stock market analysts.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2029	7378	8728

Dr Lal Pathlabs share price Target 2030

It also provides testing services to hospitals, clinics, and corporate companies. Hospitals use the company’s labs to get fast and correct results for patients. Corporate companies use these services for employee health checkups, pre-employment tests, food handling tests, and other work-related tests. These services help keep employees healthy and workplaces safe. By working with many organisations, the company helps a large number of people stay healthy. This makes the company important for both individuals and businesses. In 2030, its share price target would be ₹9842, as per stock market analysts.

Its share price would be between ₹8610 to ₹9842 in 2030, as per stock market analysts.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2030	8610	9842

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	8610	8841
February	8707	8934
March	8734	9058
April	8774	9102
May	8885	9187
June	8910	9257
July	8941	9341
August	8990	9398
September	9054	9445
October	9112	9541
November	9242	9667
December	9414	9842

Share Price Target 2040

It uses advanced machines and modern technology to give fast and correct reports. Its automated systems help handle samples safely and reduce mistakes. Digital tools help store patient information, track samples, and give online reports. People can also book tests online and make digital payments easily. The company keeps updating its machines and software to follow the latest medical rules. This use of technology helps the company give reliable results and makes testing simple, quick, and safe for patients. In 2040, its share price target would be ₹15410, as per stock market analysts.

Its share price would be between ₹14061 to ₹15410 in 2040, as per stock market analysts.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2040	14061	15410

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	14061	14474
February	14101	14557
March	14154	14641
April	14278	14788
May	14357	14890
June	14415	14978
July	14587	15074
August	14741	15168
September	14858	15190
October	14900	15231
November	14934	15289
December	15074	15410

Share Price Target 2050

The company has a large team of trained professionals, like pathologists, lab technicians, radiologists, sample collectors, and customer support staff. All of them follow safety rules, keep the labs clean, and handle samples carefully. The staff receives regular training to learn new methods and use new technology. They make sure that reports are correct and patients are treated kindly. Their skills and hard work help the company maintain trust and provide good service. In 2050, its share price target would be ₹20680, as per stock market analysts.

Its share price would be between ₹19458 to ₹20680 in 2050, as per stock market analysts.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2050	19458	20680

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	19458	19841
February	19500	19987
March	19584	20104
April	19625	20125
May	19678	20174
June	19785	20212
July	19852	20275
August	19930	20315
September	19984	20374
October	20102	20418
November	20158	20525
December	20257	20680

Should I buy Dr Lal Pathlabs stock?

Year	Minimum Price (Rs)	Maximum Price (Rs)
2025	2293	3674
2026	3484	4979
2027	4725	6308
2028	6180	7572
2029	7378	8728
2030	8610	9842
2040	14061	15410
2050	19458	20680

This stock could be a good stock for long-term investment because the company is strong, trusted, and growing its labs across India. But in the short term, its profit might go down a little because it is spending money to expand, and there is competition. So it is a good choice if you want slow and steady growth and are okay with small ups and downs in the stock price.

Dr Lal Pathlabs earnings results

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales +	1,330	1,581	2,087	2,017	2,227	2,461	2,600
Expenses +	987	1,145	1,526	1,527	1,617	1,764	1,860
Operating Profit	344	436	561	490	609	698	739
OPM %	26%	28%	27%	24%	27%	28%	28%
Other Income +	55	51	52	42	69	91	104
Interest	15	16	30	38	29	22	20
Depreciation	73	77	108	150	144	142	147
Profit before tax	310	394	475	344	505	625	676
Tax %	27%	25%	26%	30%	28%	21%
Net Profit +	228	296	350	241	362	492	540
EPS in Rs	27.11	34.99	41.37	28.65	42.85	58.28	63.84
Dividend Payout %	44%	57%	29%	42%	56%	0%	—

Key Metrics

TTM PE Ratio	PB Ratio	Dividend Yield	Sector PE	Sector PB	Sector Div Yld
47.67	11.54	0.79%	37.31	5.90	0.58%

Peers & Comparison

Stock	PE Ratio	PB Ratio	Dividend Yield
Dr. Lal PathLabs Ltd	52.29	11.54	0.79%
Max Healthcare Institute Ltd	105.10	12.05	0.13%
Apollo Hospitals Enterprise Ltd	72.95	9.50	0.17%
Fortis Healthcare Ltd	89.62	7.57	0.11%

Is Dr Lal Pathlabs stock good to buy? (bull case & bear case)

Bull Case:

• The company has zero debt, so it is safe and stable.
• Profit has grown well, with some quarters showing 16% and even 80% growth compared to last year.
• The company’s revenue keeps increasing every year.
• The health test market in India is growing by 8%–10% every year, which helps the company grow.
• It is opening many new labs in different cities and towns.
• The company is a trusted brand, so more people choose it for tests.
• Its big network and good cash flow help it grow for the long term.

Bear Case:

• Profit margins are going down because the company is spending more on expansion, falling by 1%–2% in some quarters.
• There is strong competition from many small labs and new online testing companies offering cheaper tests.
• If the company’s growth slows even a little, the high stock price can fall quickly.
• More than 50% of revenue comes from North India, so slow growth there can hurt the company.

Conclusion

It is a well-known and trusted testing company with many labs, growing profits, and no debt, which makes it a safe choice for long-term investors. The demand for health tests in India is also increasing, which helps the company grow in the future. But the stock price is already high, profits may go down a little because the company is spending money to open more labs, and there is strong competition, so the share price may go up and down in the short term. It is a good stock if you want slow, steady growth and do not mind small ups and downs.

FAQs